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It is well known that the natural history of chronic heart failure (CHF),regardless of age and aetiology,is
characterized by progressive cardiac dysfunction refractory to conventional cardiokinetic, diuretic and peripheral
vasodilator therapy. Several previous studies, both in animals and humans, showed that the key pathogenetic
element of CHF negative clinical evolution is constituted by myocardial remodeling. This is a complex pathologic
process of ultrastructural rearrangement of the heart induced by various neuro-humoral factors released by cardiac
fibrocells in response to biomechanical stress connected to chronic haemodynamic overload. Typical features of
myocardial remodeling are represented by cardiomyocytes hypertrophy and apoptosis, extracellular matrix
alterations, mesenchymal fibrotic and phlogistic processes and by cardiac gene expression modifications with fetal
genetic program reactivation. In the last years, increasing knowledge of subtle molecular and cellular mechanisms
involved in myocardial remodeling has led to the discovery of some new potential therapeutic targets capable of
inducing its regression. In this paper our attention is focused on the possible use of antiapoptotic and antifibrotic
agents, and on the fascinating perspectives offered by the development of myocardial gene therapy and, in
particular, by myocardial regenerative therapy.
Keywords: Chronic heart failure, Myocardial remodeling, Molecular therapeutic targets, Myocardial gene and
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Treatment of heart failure has been long based on three
main drugs to augment contractile force and lighten the
heart’s workload, i.e. cardiokinetics to correct ventricular
contractile deficit, diuretics to eliminate hydric-saline
retention and vasodilators to reduce increased systemic
resistances caused by peripheral vasoconstriction.
Hydric-saline retention and vasoconstriction result from
the release of adrenergic amines, angiotensin and aldos-
terone in circulation due to the reflex activation of ad-
renergic and renin-angiotensin systems triggered off by
the drop of intraaortic pressure determined by systolic
output reduction [1,2]. However, this neuro-hormonal
response aimed at maintaining peripheral circulatory
pressure tone and ensuring vital organs perfusion further
jeopardizes myocardial kinesis because it determines* Correspondence: distef@unict.it
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distribution, and reproduction in any mediumvolume and pressure overload. Moreover, it explains the
utility of diuretic and vasodilatative therapy to restore
normal circulation.Physiopathology of chronic heart failure (CHF)
In the chronic form of heart failure, whether idiopathic
or secondary to various causes (inflammatory processes,
ischemic syndromes, neuromuscular diseases, anthracy-
cline induced toxicity, metabolic disorders, etc.) and
generally linked to dilatative cardiomyopathies in child-
hood and adolescence, the therapeutic effectiveness of
the above mentioned drugs tends to fade progressively
over time. This may be because neuro-hormonal re-
sponse linked to ventricular contractile deficiency can be
overenhanced and thus severely damage heart function.
In fact, while downregulation of adrenergic receptors
resulting from the presence of excessive circulating
amines inhibits adequate contractile response to adren-
ergic stimuli, increment of hydric-saline retention andd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Vicious circle inpairing myocardial contractility in chronic heart failure.
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after- load disproportionately. These effects result in
more precarious heart performance giving rise to a vi-
cious circle with progressive myocardial dysfunction that
becomes more and more refractory to conventional
treatment [3,4] (Figure 1). Molecular cardiology studies
carried out in the last ten years have revealed some sub-
tle pathogenetic mechanisms causing the progression of
CHF and its resistance to traditional treatment [5]. It
seems that in addition to the above-mentioned negative
haemodynamic effects on pre and after-load, some
pathologic modifications induced by adrenergic amines,
angiotensin and aldosterone in the myocardial ultra-
structure at cellular and extracellular level may be
involved in the deterioration of cardiac functionality.
Furthermore, the same neuro-hormonal response can
also be expressed to a greater degree inside the cardiac
muscle and includes, together with catecholamines,
angiotensin and aldosterone, other molecules such as
endothelin, various proinflammatory cytokines (TNF-α,
interleukin-β, interleukin-6) and some myocytic and vas-
cular growth factors. These substances are released by
cardiomyocytes after their mechano- receptors stimula-
tion by biomechanical stress linked to chronic pressure
and volume hemodynamic overload [6,7].
Myocardial remodeling as leading cause of
progressive cardiac dysfunction
Numerous experimental studies have shown that the
humoral factors secreted by mechanically stressed cardi-
omyocytes activate a vast network of intra and intercel-
lular transduction signals. Acting in autocrine and
paracrine fashion in the same cardiomyocytes and in the
surrounding tissues, they are able to alter myocardial ultra-
structure and determine cardiac fibrocells hypertrophyand/or apoptosis, mesenchymal fibrotic and inflamma-
tory processes and induce modifications in cardiac
gene expression [8-11]. This series of events is the
basis of so called “myocardial remodeling” [12], i.e. a
complex phenomenon of ultrastructural cardiac re-
arrangement that today, because of the sensible
changes in cardiomyocytes viability, energetic metab-
olism and kinetic and electric properties and also in
the cytoskeleton and extracellular matrix composition,
is considered the key pathogenetic factor of CHF and
of its natural history marked by inexorable, progres-
sive cardiac dysfunction [13,14] (Figure 2).
One of the salient points in myocardial remodeling is
altered cardiac gene expression, i.e. reactivation of fetal
cardiac genetic program that can manifest with re-
expression of genes that are hyperactive during the fetal
period, including the gene of β-myosin (protein at low
ATPasic activity poorly efficient in contractile function),
some proapoptotic genes, and the gene of α subunit of
Na,K dependent ATPase (an enzymatic variant having
poor membrane stabilizing capacity). It may also involve
inhibition of genes that are hyperactive in the adult
heart, such as the genes of the sarcotubular ATPase
(enzyme determining calcium reuptake from contractile
filaments and hence essential for diastolic function), of
β-adrenergic receptors (crucial for systolic activity), and
of lipid β-oxidation (the main source of energy for the
myocardium whose inhibition turns cardiac energetic
metabolism into glycolysis that is poorly efficient for the
heart) [15]. In recent studies on cardiac gene expression
in various experimental models of cardiovascular dis-
eases associated with heart failure, Kuwahara and Nakao
[16] identified a series of “transcriptional pathways”
involved in cardiac remodeling and connected to the
reactivation of fetal cardiac genes implicated in the
Figure 2 Intramyocardial neuro-humoral response to biomechanic stress induced by chronic haemodinamic overload. Release of
humoral factors determinig myocardial remodeling and progression of cardiac dysfunction in chronic heart failure.
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rhythm disorders.
Therefore, remodeling related processes determine
marked changes in myocardium phenotype that make it
functionally more precarious. These changes include
anomalies involving important molecules regulating sys-
tolic and diastolic function (as alfa- myosin and sarco-
tubular ATPase), cytoskeletal proteins and extracellular
matrix composition. In the cytoskeleton, enhanced pro-
tein filament expression and increased microtubular net-
work density can lead to sarcomere disorganization,
while in extracellular matrix, fibroblastic hyperplasia
and augmented collagen synthesis with production of
rigid type 1 collagen fibrils can reduce ventricular
compliance [17].
Instead of representing a useful compensatory event,
in the long run also myocardial hypertrophy triggered
off by chronic hemodynamic overload may damage the
heart. Increased ventricular wall thickness initially
reduces parietal stress (and hence oxygen requirement)
and increases heart contractility. However, the compen-
satory effect is markedly curbed by subsequent re-
expression of pro-apoptotic embryo-fetal genes and by
fibroblastic hyperplasia with increased collagen synthe-
sis, caused by the same biochemical mediators determin-
ing hypertrophy. Loss of contractile tissue due to
cardiomyocytes apoptosis and mesenchymal fibrosis
determined by increased collagen synthesis makes theheart dilate and stiffen, causing systolic and diastolic
dysfunction [18] (Figure 3). Thus, the hypertrophy that
occurs during cardiac remodeling differs from physiolo-
gically induced hypertrophy during exercise training
where the growth signals of myocardial fibers are ac-
companied by biochemical signals favoring their troph-
ism and survival. Diversely in remodeling, growth
signals are associated with signals promoting cardiomyo-
cytes apoptosis resulting in the loss of contractile ele-
ments that are replaced by fibrous tissue [19-21]
(Figure 4). In addition, the two types of hypertrophy
have different morphological expression. In physiological
hypertrophy the cardiomyocytes grow evenly in length
and width, whereas in pathological hypertrophy they be-
come wider during pressure overload and longer during
volume overload, and this can disrupt sarcomere align-
ment with inevitable negative repercussions on cardiac
function [22]. Such acquisitions on cardiac hyper-
trophy heterogeneity have stimulated numerous studies
aimed at better understanding of the subtle molecular
mechanisms underlying the two types of hypertrophy,
physiological and pathological, in order to draw useful
therapeutic indications. A recent important review [23]
indicates that the myocardium presents increased pro-
tein synthesis, cellular growth and increment of extra-
cellular matrix in both pathological and physiological
hypertrophy, whereas it differs greatly from a bio-
chemical, metabolic and molecular viewpoint in the
Figure 3 Alterations induced by chronic biomechanic stress on cardiac muscle. Note that beneficial effects of myocardial hypertrophy on
cardiac performance are counteracted by induction of apoptotic and fibrotic processes.
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shows concomitant apoptotic, oxidative and inflam-
matory events, and glycolysis, that produces less
energy than lipid beta-oxidation, prevails in energetic
metabolism. On the contrary, in physiological hyper-
trophy lipid β-oxidation is accompanied by signaling
pathways activation leading to the expression of bio-
chemical mediators improving trophism and cardio-
myocytes survival. Furthermore, it has been observed
that most endocellular signals promoting physiological
hypertrophy are linked to kinase AKT system activa-
tion, while those of pathological hypertrophy occur
after G-protein system activation [23].Figure 4 Different response to growth stimuli in physiologic and pathTherapeutic strategies to reverse myocardial
remodeling
The recent advances achieved in the knowledge of mo-
lecular pathogenetic mechanisms of CHF have paved the
way for new therapeutic approaches aimed at reversing
myocardial remodeling and combating apoptotic and fi-
brotic processes responsible, respectively, for cardiomyo-
cytes loss and myocardial wall rigidity, and thus
jeopardizing global heart function.
Use of antagonists of neuro-humoral factors
This strategy represents the first approach to antiremo-
deling treatment and used antagonists of the variousologic cardiac hypertrophy.
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and involved in myocardial remodeling : i.e. ACE-inhibitors
and sartanics for angiotensin; spironolactone and natri-
uretic peptides for aldosterone; β- blockers for adrenergic
amines; direct antagonists (bosentan) for endothelin;
monoclonal antibodies and soluble fusion receptors for
cytokines [12,24]. The most commonly used β-blocker is
cardvedilol that reduces oxygen requirements by slowing
heart rhythm and by decreasing afterload through periph-
eral vasodilatation. It also possesses an antioxidant action
and recovers intrinsic cardiac inotropism by increasing the
number of adrenergic receptors and determining overex-
pression of α-myosin, a protein at high ATPasic activity, in
cardiomyocytes [25,26]. Anticytokines were used mainly
against TNF-α which usually presents very high serum
concentrations in patients with CHF. Nonetheless, it must
be underlined that to date clinical experiences using all
these drugs, alone or in combination, are rather fragmen-
tary and the results do not always agree with the benefits
found in animal studies. Moreover, it must be kept in mind
that there are still no controlled prospective studies con-
firming long-term efficacy. The results obtained using
endothelin antagonists are particularly disappointing [27],
and those using anti-TNFα (both monoclonal antibodies
and soluble receptors) are surprisingly modest even if this
cytokine represents the most important biochemical mar-
ker of inflammatory processes in CHF [28-30]. On the
other hand, pentoxfylline, an agent able to downregulate
TNF synthesis and induce a wide immunomodulating ac-
tion and vasodilatation, appears to be a potentially effi-
cient anticytokine [31]. The scarce effectiveness of directFigure 5 Potential therapeutic use of B1 and B2 kinin receptors (B1R,
damage.TNF antagonists is probably linked to the multiple bio-
chemical mechanisms causing inflammation in heart fail-
ure and to the frequent combination of inflammatory
and oxidative events. Hence, in the future better clinical
results may be achieved using substances targeting mul-
tiple proinflammatory signals. In effect, preclinical trials
in rats reported that some substances such as histone
deacetylase inhibitors could represent an innovative and
very promising class of therapeutic agents thanks to their
broad anti-inflammatory spectrum associated to antia-
poptotic and antifibrotic properties [32].
Use of antiapoptotic and antifibrotic agents
The increasing knowledge of the biochemical signals
activated during myocardial remodeling have recently fo-
cused scientists’ attention on agents that can directly re-
verse the damaging apoptotic and fibrotic processes that
impair heart function [33,34].
Concerning apoptosis, in various experimental animal
models of CHF, apoptosis was hindered by substances
that stimulate cardiomyocytes survival or inhibit death
signals. Some potential therapeutic agents are cardiotro-
phin, a non inflammatory cytokine capable of activating
GP-130-LIF protein and interrupting proapoptotic sig-
nals [22,35]; tetrandrine, an alkaloid isolated from a
Chinese herb matrix that inhibits the ros-dependent
ERC-1 signal that causes cardiac apoptosis and fibrosis
[36]; and heme oxygenase-1 that frees carbon monoxide
(CO) from the heme and seems capable of stabilizing
mitochondrial membranes and inhibiting cytochrome C
release that activates caspase enzymes inducing apoptosis.B2R) modulators to prevent anthracycline-induced myocardial
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potential therapeutic use of CO-releasing molecules
[37,38]. Other therapeutic advances against apoptosis use
substances that activate the AKT biochemical system,
which, as previously mentioned, protects cardiomyocytes
and favors physiological hypertrophy, maintaining mito-
chondrial intactness [39]. Studies on anthracycline-
induced chronic cardiomyopathy [40] postulated the use
of molecules able to modulate cardiac bradykinin BR1 and
BR2 receptors that respectively inhibit and stimulate the
AKT system. It has been seen that one of the mechanisms
by which anthracycline can damage the heart is linked to
BR1 receptor upregulation (and increased BR1/BR2 ratio).
Such upregulation suppresses the AKT system and favors
inflammatory and apoptotic signals activation that can
be blocked by BRI antagonists or BR2 stimulators [41]
(Figure 5). Erythropoietin has also been used to treat
anthracycline cardiomyopathy. It activates the AKT sys-
tem and seems able to improve trophism and heart
muscle oxygenation, and hence cardiomyocytes and ves-
sels cells survival, by releasing anti-inflammatory, antia-
poptotic and antioxidant factors [42] (Figure 6). Another
molecule that seems to significantly activate the AKT
system is IGF-1 and patients with CHF often present
low serum IGF-1 levels correlated with the degree of
systolic dysfunction [43]. However, to date there are no
studies on the possible use of this substance.
As regards antifibrotic treatment, preclinical studies
(in murine models) have frequently shown that fibrosis
can be curbed by various substances, such as inhibitors
of TGF-β, a growth hormone that stimulates myofibro-
blasts collagen synthesis [44] and torasemide. The latter
is a loop diuretic capable of inhibiting procollagen type 1
carboxy- terminal proteinase and lysyl oxidase enzymes
that play an important role in promoting rigid and in-
soluble type I collagen fibrils production and depositionFigure 6 Possible mechanism by which erythropoietin is cardioprotec[45,46]. Other useful substances are represented by the
inhibitors of some specific micro ribonuleic acids whose
overexpression is strictly associated with myocardial
fibrosis [47].
Future perspectives
Alongside these measures targeting apoptotic and fi-
brotic processes, the most noteworthy perspectives in
the treatment of CHF are those connected to the devel-
opment of myocardial gene therapy and myocardial re-
generation therapy.
Myocardial gene therapy
In the field of cardiovascular research the potential of
gene therapy has been mostly explored in several models
of inherited monogenic cardiac diseases. Recent insights
concerning the molecular mechanisms and the identifi-
cation of numerous genes and relative coded proteins
involved in the pathogenesis of various acquired heart
diseases have extended its application to heart failure.
Myocardial gene therapy consists of an intramyocar-
dial transfer of specific genes for some molecular targets
involved in myocardial remodeling through viral (mainly
adenovirus) or non viral vectors (plasmids or oligonu-
cleotids). Extensive preclinical studies have shown that
this therapeutic approach is able to modulate calcium
homeostasis in cardiac myocytes, manipulate adrenergic
receptors related biochemical signals and increase cardi-
omyocytes resistance to apoptosis. The results of these
studies foresee the potential of a “molecular ventricular
assistance” in the failing heart [48].
Over the last few years, recent advances in myocardial
gene therapy include improved vectors provided with
greater trophism for myocardial cells and more efficient
delivery methods, and have paved the way for translating
experimental observations into therapeutic strategies intive.
Figure 7 Effects of anthracycline on cardiac stem cells and on
mature cardiomyocytes.
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plasmic endoplasmin reticulum calcium ATPase (SER-
CA2a) was initiated after a satisfactory phase 1 study.
This enzyme plays a crucial role in regulating calcium
cycling (and hence modulating cardiac contractility) and
is downregulated in CHF [51]. The SERCA2a gene was
transferred via a recombinant adeno-associated virus
vector in 39 patients with advanced CHF utilizing percu-
taneous intracoronary infusion as delivery method [52].
Recently, the results of this trial have conclusively shown
positive biological outcome of the patients and have
clearly demonstrated that SRCA2a is an important
therapeutic target in CHF [53]. At present, clinical ex-
perimentation includes two other on-going trials target-
ing SERCA2a in the United Kingdom and in France and
some targeting adenylyl-cyclase (AC6 isoform), an en-
zyme activated by beta-adrenergic receptors stimulation
that plays an important role in cardiac inotropism and is
downregulated in the failing heart [51].
Whether also the results of these studies confirm the
clinical efficacy and safety of the treatment and other
molecular targets (specially antiapoptotic signals) sus-
ceptible to gene manipulation will be successfully
explored [54] in the near future, myocardial gene ther-
apy will certainly represent a viable and important tool
to improve cardiac performance in patients with CHF.
Myocardial regenerative therapy
Myocardial regenerative therapy has been adopted to re-
place the loss of cardiomyocytes and repair damaged
myocardial tissue. This therapy is based on myocardial
transplantation of stem cells derived from embryos,
muscle, endothelium, bone marrow, etc. capable of dif-
ferentiating into myocardial and endothelial cells and
vascular myocytes under special conditions in vitro. The
majority of these fascinating experimental researches
have been carried out in acute and chronic ischemic car-
diovascular pathologies and have mainly utilized bone
marrow-derived mesenchymal stem cells that, together
with embryonic-derived stem cells (rejected as they may
determine teratomas), possess major cardiogenic poten-
tial [55]. However, results in clinical trials have not been
very encouraging [56,57] and may be due to the adverse
microenvironment in injured tissues of the failing heart
(specially ischemia related). Indeed, the presence of in-
flammation, microvascular changes, altered oxygen ten-
sion and elevated levels of catabolites can impair not
only the survival of stem cells inoculated into the myo-
cardium, but also their differentiation into cardiomyo-
cytes [58]. Nevertheless, recently great attention has
been focused on myocardial regenerative therapy follow-
ing reports that the adult heart of humans and other
animal species is not a completely postmitotic organ,
but possesses substantial regenerative potential. This isdue to the presence of resident cardiac stem cells
(RCSCs) capable of proliferating, differentiating into car-
diomyocytes, endothelial and smooth muscle vascular
cells, and migrating within the myocardium where they
normally regulate cardiac cell homeostasis [59]. Studies
in animals with ischemia-induced heart injuries revealed
that intramyocardial injection of in vitro cultured RCSCs
is able to promote myocardial and vascular tissue regen-
eration [60]. The utility of RCSCs therapy in CHF has
been mainly taken into account for anthracycline-
induced cardiomyopathy. Experimental in vitro and
in vivo studies have revealed that because of their
marked sensitivity to oxidative stress, these stem cells
are particularly damaged by anthracycline, a well known
producer of free radicals, and die more rapidly than ma-
ture cardiomyocytes. Furthermore, the ones that manage
to survive malfunction in mature cardiac cells differ-
entiation processes. Hence, in anthracycline-induced
cardiomyopathy, massive RCSCs destruction damages
physiological cardiomyocytes turnover and regeneration,
leads to accumulation of ageing myocytes (mechanically
less efficient) in the heart, and, at the same time, pre-
vents the onset of repair processes of myocardial damage
caused by apoptosis and fibrosis [61] (Figure 7). Intra-
myocardial injection of in vitro expanded RCSCs in rats
with anthracycline-induced cardiomyopathy not only
generated new cardiomyocytes and repopulated the
heart with contractile elements, but also replaced fi-
brotic areas leading to structural and functional restor-
ation of damaged myocardium [61] (Figure 8). It is clear
that these results need to be confirmed by further stud-
ies corroborating the long term efficacy of regenerative
therapy prior to their use in humans. If the results are
positive, it is likely that intramyocardial injection of
RCSCs, isolated from biopsy samples and expanded
Figure 8 Effects of intramyocardial injection of cardiac stem
cells in rats with anthracycline - induced cardiomyopathy.
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key therapeutic tool to prevent or treat severe heart dys-
function in patients with anthracycline-induced cardio-
myopathy. In other forms of CHF where the RCSCs
reserve pool is presumably not as severely impaired as in
anthracyclinic cardiomyopathy, another emerging type
of regenerative therapy could be intramyocardial delivery
of trophic substances (various growth factors and non
inflammatory cytokines) capable of stimulating cardiac
stem cell proliferation and differentiation in situ [62].
This therapeutic approach is less invasive as it does not
require stem cells from endomyocardial biopsy for
in vitro cultures and subsequent transplant. According
to diverse experimental studies, such therapy exploits
the fact that RCSCs possess specific receptors for these
trophic substances and, once activated, not only prolifer-
ate and differentiate in myocardial and endothelial cells,
but they also acquire the capacity to secrete trophic fac-
tors [63]. Acting in a autocrine and paracrine manner,
these factors can further stimulate RCSCs growth and
differentiation, and can also play a key beneficial role in
myocardial remodeling. They achieve this by protecting
cardiomyocytes against apoptosis, stimulating neoangio-
genesis and inhibiting fibrosis, thus regulating extracel-
lular matrix turnover [64,65]. The ability to produce
trophic substances is not limited to RCSCs, but is shared
by all stem cells, in particular mesenchymal stem cells
(MSCs) [66]. It has been seen that such cells produce
and secrete a large variety of cytokines, chemokines and
growth factors [67] which all present elevated levels in
their culture medium, regardless of the cell line theydifferentiate into [68]. Experimental studies on
myocarditis-induced dilated cardiomyopathy in rats
revealed the central role played by the paracrine effects
of these humoral factors released by MSCs in reversing
myocardial remodeling [69]. Other studies in animals
with ischemic cardiac lesions demonstrated that intra-
myocardial delivery of conditioned medium (CM) from
MSCs possesses a marked cytoprotective effect and
favors cardiac repair. This protective effect on cardio-
myocytes is greater when the medium is derived from
genetically modified MSCs overexpressing the AKt-1
gene that is known to codify anti-apoptotic molecules
synthesis [66]. These findings are of paramount import-
ance in regenerative myocardial therapy as culture
medium of stem cells derived from tissues that are easier
to extract than heart tissue could be used as sources of
trophic factors to stimulate RCSCs and activate repair-
ing and cardioprotective processes. Experimental stud-
ies on perinatal hypoxic-ischemic brain damage in rats
reported similar findings. In these investigations
humoral factors present in culture medium of pluripo-
tent stem cells derived from adipose tissue stroma were
used to stimulate resident cerebral stem cells prolifera-
tion and differentiation for repairing cerebral damage
[70,71]. In the heart, vascular endothelial growth factor
and hepatocyte growth factor determine major RCSCs
activation in situ, but recent studies in animals with
acute and chronic cardiac ischemic lesions have also
identified some synthetic molecules, for example hyalur-
onan mixed esters of butyric and retinoic acid, affording
myocardial repair [65].
If all these extremely important experimental observa-
tions are confirmed by further studies, and if they can be
reproduced in humans, in all likelihood intramyocardial
delivery of a cocktail of natural and synthetic trophic
substances capable of interacting positively in cardiac re-
modeling and myocardial regeneration can become the
treatment of choice in CHF in the near future. More-
over, it may be the only therapy that can overcome the
need for heart transplant that today represents the last
chance for the survival of patients with this very severe
disease. Finally, the combination of myocardial gene and
regenerative therapy may achieve even better results.
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